Cardiovascular Diseases Clinical Trial
Official title:
PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy
The main purpose of this study is to evaluate Fetal Medicine Foundation's pre-eclampsia risk calculator using maternal characteristics, first trimester serum placental growth factor (PlGF) and mean arterial pressure (MAP) in a Finnish general population. Condition or disease: pre-eclampsia, intrauterine growth restriction, polycystic ovary syndrome
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | December 31, 2041 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Mothers Inclusion Criteria for PEPPI-study - Pregnant (first trimester) - Understands Finnish - =18 years - Signed informed consent Exclusion Criteria - Multiple pregnancy - Miscarriage/termination of the index pregnancy - No first trimester blood sampling Inclusion Criteria for FERPPI-study - Participates in PEPPI-study (criteria above) - Blood samples at first and third trimester of pregnancy - Permits blood sampling from the umbilical cord when the baby is born Exclusion Criteria - No first or third trimester blood sampling - No umbilical cord blood sample after baby is born Fathers Inclusion Criteria - Biological father to the child born for the mother who participated in PEPPI study - =18 years - Signed informed consent Exclusion Criteria • Does not understand Finnish Children Inclusion Criteria for PEPPI-study - Born to mother who participated in PEPPI study - Signed informed consent from parent(s) Exclusion Criteria • No consent from parent(s) Inclusion Criteria for PEPPI-offspring study • Mother in risk-, control-, or PCOS group during PEPPI-study with ultrasound information at gestational weeks 30-32 or a mother who developed pre-eclampsia during the pregnancy regardless of their study group during PEPPI-study Exclusion Criteria • Mother/father declines participation Inclusion Criteria for FERPPI-study - Signed informed consent from parent(s) - Mother has blood samples taken at first and third trimester (iron status) - Child has blood samples taken at birth and at 3 months of age Exclusion Criteria - No consent from parent(s) - No blood samples from mother - No blood samples from child |
Country | Name | City | State |
---|---|---|---|
Finland | The Wellbeing Services County of North Ostrobothnia | Oulu |
Lead Sponsor | Collaborator |
---|---|
Oulu University Hospital | Academy of Finland, Finnish Medical Foundation, PerkinElmer, Inc., Roche Diagnostics, Sigrid Jusélius Foundation, University of Oulu |
Finland,
Ashraf UM, Hall DL, Rawls AZ, Alexander BT. Epigenetic processes during preeclampsia and effects on fetal development and chronic health. Clin Sci (Lond). 2021 Oct 15;135(19):2307-2327. doi: 10.1042/CS20190070. — View Citation
Bahri Khomami M, Joham AE, Boyle JA, Piltonen T, Silagy M, Arora C, Misso ML, Teede HJ, Moran LJ. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-A systematic review, meta-analysis, and meta-regression. Obes Rev. 2019 May;20(5):659-674. doi: 10.1111/obr.12829. Epub 2019 Jan 23. — View Citation
Becker M, Hesse V. Minipuberty: Why Does it Happen? Horm Res Paediatr. 2020;93(2):76-84. doi: 10.1159/000508329. Epub 2020 Jun 29. — View Citation
Binder NK, Evans J, Salamonsen LA, Gardner DK, Kaitu'u-Lino TJ, Hannan NJ. Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation. PLoS One. 2016 Oct 6;11(10):e0163096. doi: 10.1371/journal.pone.0163096. eCollection 2016. — View Citation
Chockalingam UM, Murphy E, Ophoven JC, Weisdorf SA, Georgieff MK. Cord transferrin and ferritin values in newborn infants at risk for prenatal uteroplacental insufficiency and chronic hypoxia. J Pediatr. 1987 Aug;111(2):283-6. doi: 10.1016/s0022-3476(87)80088-4. — View Citation
Dewey KG, Oaks BM. U-shaped curve for risk associated with maternal hemoglobin, iron status, or iron supplementation. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1694S-1702S. doi: 10.3945/ajcn.117.156075. Epub 2017 Oct 25. — View Citation
Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004659. doi: 10.1002/14651858.CD004659.pub2. — View Citation
Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009 Jun;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010. — View Citation
Guy GP, Leslie K, Diaz Gomez D, Forenc K, Buck E, Khalil A, Thilaganathan B. Implementation of routine first trimester combined screening for pre-eclampsia: a clinical effectiveness study. BJOG. 2021 Jan;128(2):149-156. doi: 10.1111/1471-0528.16361. Epub 2020 Jul 1. — View Citation
Henley D, Brown S, Pennell C, Lye S, Torpy DJ. Evidence for central hypercortisolism and elevated blood pressure in adolescent offspring of mothers with pre-eclampsia. Clin Endocrinol (Oxf). 2016 Oct;85(4):583-9. doi: 10.1111/cen.13092. Epub 2016 May 26. — View Citation
Kalousova M, Muravska A, Zima T. Pregnancy-associated plasma protein A (PAPP-A) and preeclampsia. Adv Clin Chem. 2014;63:169-209. doi: 10.1016/b978-0-12-800094-6.00005-4. — View Citation
Koster MP, de Wilde MA, Veltman-Verhulst SM, Houben ML, Nikkels PG, van Rijn BB, Fauser BC. Placental characteristics in women with polycystic ovary syndrome. Hum Reprod. 2015 Dec;30(12):2829-37. doi: 10.1093/humrep/dev265. Epub 2015 Oct 25. — View Citation
Nevalainen J, Korpimaki T, Kouru H, Sairanen M, Ryynanen M. Performance of first trimester biochemical markers and mean arterial pressure in prediction of early-onset pre-eclampsia. Metabolism. 2017 Oct;75:6-15. doi: 10.1016/j.metabol.2017.07.004. Epub 2017 Jul 18. — View Citation
Nevalainen J, Skarp S, Savolainen ER, Ryynanen M, Jarvenpaa J. Intrauterine growth restriction and placental gene expression in severe preeclampsia, comparing early-onset and late-onset forms. J Perinat Med. 2017 Oct 26;45(7):869-877. doi: 10.1515/jpm-2016-0406. — View Citation
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 2016 Jun 28;6(6):e011801. doi: 10.1136/bmjopen-2016-011801. — View Citation
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613-622. doi: 10.1056/NEJMoa1704559. Epub 2017 Jun 28. — View Citation
Santos DCC, Angulo-Barroso RM, Li M, Bian Y, Sturza J, Richards B, Lozoff B. Timing, duration, and severity of iron deficiency in early development and motor outcomes at 9 months. Eur J Clin Nutr. 2018 Mar;72(3):332-341. doi: 10.1038/s41430-017-0015-8. Epub 2017 Nov 6. — View Citation
Shanmugalingam R, Hennessy A, Makris A. Aspirin in the prevention of preeclampsia: the conundrum of how, who and when. J Hum Hypertens. 2019 Jan;33(1):1-9. doi: 10.1038/s41371-018-0113-7. Epub 2018 Sep 19. — View Citation
Shao J, Lou J, Rao R, Georgieff MK, Kaciroti N, Felt BT, Zhao ZY, Lozoff B. Maternal serum ferritin concentration is positively associated with newborn iron stores in women with low ferritin status in late pregnancy. J Nutr. 2012 Nov;142(11):2004-9. doi: 10.3945/jn.112.162362. Epub 2012 Sep 26. — View Citation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reprod Biol Endocrinol. 2014 Aug 20;12:82. doi: 10.1186/1477-7827-12-82. — View Citation
Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, Singh M, Greco E, Wright A, Maclagan K, Poon LC, Nicolaides KH. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018 Jun;51(6):743-750. doi: 10.1002/uog.19039. Epub 2018 Mar 14. — View Citation
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018 Sep 1;33(9):1602-1618. doi: 10.1093/humrep/dey256. Erratum In: Hum Reprod. 2019 Feb 1;34(2):388. — View Citation
Yliniemi A, Nurkkala MM, Kopman S, Korpimaki T, Kouru H, Ryynanen M, Marttala J. First trimester placental retinol-binding protein 4 (RBP4) and pregnancy-associated placental protein A (PAPP-A) in the prediction of early-onset severe pre-eclampsia. Metabolism. 2015 Apr;64(4):521-6. doi: 10.1016/j.metabol.2014.12.008. Epub 2014 Dec 26. — View Citation
* Note: There are 23 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate | Severe hypertension (blood pressure [BP]= 160/110) or mild hypertension (BP=140/90) = 20 weeks gestation in conjunction with one of the following: elevated liver enzymes, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, an indicated preterm birth before 32 weeks of gestation owing to hypertension-related disorders, a fetus that was small for gestational age (SGA, below 3rd percentile) adjusted for sex and race or ethnic group, fetal death after 20 weeks of gestation, or neonatal death | 20 weeks through discharge following delivery | |
Primary | Severe Hypertension | Women who had severe hypertension only and those who had severe hypertension with elevated liver enzyme levels, thrombocytopenia, elevated serum creatinine levels, eclamptic seizure, medically indicated preterm birth, fetal-growth restriction, or fetal death after 20 weeks of gestation, or neonatal death. | 20 weeks through discharge following delivery | |
Primary | Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels | Elevated liver enzyme levels are specified as an aspartate aminotransferase level of = 100 U/l. Women who met more than one component of the primary outcome are counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome. | 20 weeks through discharge following delivery | |
Primary | Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia | Thrombocytopenia defined as a platelet count of <100 × 109/l. Women who meet more than one component of the primary outcome are counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome. | 20 weeks through discharge following delivery | |
Primary | Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level | Elevated serum creatinine defined as =90 µmol/l. Women who meet more than one component of the primary outcome are counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome. | 20 weeks through discharge following delivery | |
Primary | Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure | Women who meet more than one component of the primary outcome are counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome. | 20 weeks through discharge following delivery | |
Primary | Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32-34-37 Weeks of Gestation Owing to Hypertension-related Disorders | Women who meet more than one component of the primary outcome are counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome. | 20 weeks through discharge following delivery | |
Primary | Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the - 2 SD) Adjusted for Sex and Race or Ethnic Group | Women who meet more than one component of the primary outcome are counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome. | 20 weeks through discharge following delivery | |
Primary | Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death | Women who meet more than one component of the primary outcome are counted for each component. Therefore, the number of women for all individual components combined is greater than the number of women with the primary outcome. | 20 weeks through discharge or prior to discharge following delivery admission | |
Primary | Prevalence of high pre-eclampsia risk score in women with PCOS compared to non-PCOS women | Pre-eclampsia risk score is calculated with LifeCycle risk calculation program and a risk of 1:100 or higher is considered as high risk for pre-eclampsia. | at 13 gestational weeks | |
Primary | 11. All the above mentioned outcomes (1-10) in PCOS group compared to non-PCOS group. | As described above. | 13 gestational weeks through discharge following delivery | |
Primary | The height of the child during the first year of life. | Measurement of height (cm) | At 0, 3 and 6-12 months of age | |
Primary | The weight of the child during the first year of life. | Measurement of weight (g, kg) | At 0, 3 and 6-12 months of age | |
Primary | The body mass index (BMI) of the child during the first year of life. | Measurements of height (cm) and weight (kg) combined as BMI (kg/m2) | At 0, 3 and 6-12 months of age | |
Primary | Basic blood count | B-Hb, B-Leuk, B-Hkr, B-Eryt, E-MCV, E-RDW, E-MCH, E-MCHC, B-Trom | At 0, 3 and 6-12 months of age | |
Primary | Ferritin | At 0, 3 and 6-12 months of age | ||
Primary | Hepcidin | At 0, 3 and 6-12 months of age | ||
Primary | Saturation of transferrin | At 0, 3 and 6-12 months of age | ||
Primary | Hypersensitive-C-reactive protein | At 0, 3 and 6-12 months of age | ||
Primary | Anti-mullerian hormone | At 3 and 6-12 months of age | ||
Primary | Cortisol | At 3 and 6-12 months of age | ||
Primary | Corticotropin | At 3 and 6-12 months of age | ||
Primary | Dehydroepiandrosterone | At 3 and 6-12 months of age | ||
Primary | Progesterone | At 3 and 6-12 months of age | ||
Primary | Inhibin-B | At 3 and 6-12 months of age | ||
Primary | Luteinizing hormone | At 3 and 6-12 months of age | ||
Primary | Follicle stimulating hormone | At 3 and 6-12 months of age | ||
Primary | Testosterone (boys) | At 3 and 6-12 months of age | ||
Primary | Estradioli (girls) | At 3 and 6-12 months of age | ||
Primary | Vitamin D | At 3 and 6-12 months of age | ||
Primary | Calcium | At 3 and 6-12 months of age | ||
Primary | Phosphate | At 3 and 6-12 months of age | ||
Primary | Alkaline phosphatase | At 3 and 6-12 months of age | ||
Primary | Parathyroid hormone | At 3 and 6-12 months of age | ||
Primary | Clinical examination of genitals | Measurement of perineum with centimeters (cm) | At 0, 3 and 6-12 months of age | |
Primary | Clinical examination of mammary glands | Measurement with millimeters (mm) | At 3 and 6-12 months of age | |
Primary | Sebum measurement | Measurement is done with Sebumeter ®. The cassette is placed on the skin for a defined length of time and then returned to the aperture. The change in the amount of light transmission represents the sebum content of the tape, which is displayed in units from 0-350. | At 3 and 6-12 months of age | |
Primary | Heart auscultation with stethoscope. | At 3 and 6-12 months of age | ||
Primary | Ultrasound scan of the heart (echo) | At 3 and 6-12 months of age | ||
Primary | Birth Weight | Grams | At birth | |
Primary | Small for Gestational Age | A baby whose birth weight is less than the - 2 standard deviations is considered to be small for gestational age (adjusted for sex and race or ethnic group) | At birth | |
Primary | Large for gestational age | A baby whose birth weight is more than the + 2 standard deviations is considered to be small for gestational age (adjusted for sex and race or ethnic group) | At birth | |
Primary | Admission to NICU | NICU denotes neonatal intensive care unit. | Delivery through discharge up to 18 weeks | |
Primary | Apgar Score =3 at 5 Minutes | At birth | ||
Primary | Fetal iron deficiency | Fetal iron deficiency defined by reticulocyte hemoglobin < 29 pg from umbilical cord blood collected at birth | At birth | |
Primary | Iron deficiency during third trimester of pregnancy | Iron deficiency defined as serum ferritin < 30 µg/l at gestational weeks 30-32 with or without anemia defined as Hb = 110 g/l. | At 30-32 weeks of gestation | |
Primary | Severe iron deficiency during third trimester of pregnancy | Iron deficiency defined as serum ferritin < 15 µg/l at gestational weeks 30-32 with or without anemia defined as Hb = 110 g/l. | At 30-32 weeks of gestation | |
Secondary | Pre-eclampsia (Mild, Severe, HELLP Syndrome, Eclampsia). | HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count. | 20 weeks through discharge following delivery. | |
Secondary | Superimposed Pre-eclampsia (Mild, Severe, HELLP Syndrome, Eclampsia). | Women with Hypertension before pregnancy week 20. HELLP denotes hemolytic anemia, elevated liver enzymes, and low platelet count. | 20 weeks through discharge following delivery. | |
Secondary | Pregnancy Associated Hypertension. | Women with Hypertension after pregnancy week 20. | 20 weeks through discharge following delivery. | |
Secondary | Medically Indicated Delivery Because of Hypertension. | 20 weeks through discharge following delivery. | ||
Secondary | Fetal Weight Estimation under 3rd percentile at gestational weeks 30-32 ultrasound scan. | 30-32 weeks. | ||
Secondary | Abnormal uterine artery pulsatility index at gestational weeks 30-32 ultrasound scan | According to calculator provided by Fetal Medicine Foundation (https://fetalmedicine.org/research/utpi). | At 30-32 weeks. | |
Secondary | Aspartate Aminotransferase =100 U/Liter. | 20 weeks through discharge. | ||
Secondary | Creatinine =90 µmol/l. | 20 weeks through discharge. | ||
Secondary | Massive postpartum hemorrhage. | Massive postpartum hemorrhage defined= 1000ml blood loss within 24 hours after child birth. | From delivery to 24 hours after child birth | |
Secondary | Premature Rupture of Membranes. | If the water breaks before the 37th week of pregnancy, it is called preterm premature rupture of membranes (PPROM). | From 22nd gestational week until delivery | |
Secondary | Placental Abruption. | Defined as the placenta separates from the inner wall of the uterus before birth. | From 22nd gestational week until delivery | |
Secondary | Gestational Diabetes. | Defined as abnormal glucose tolerance test during pregnancy (= 5.3 mmol/l (0 h), = 10.0 mmol/l (1 h) and/or = 8.6 mmol/l (2 h). Treatment either with diet or medicine (metformin and/or insulin therapy). | From gestation until delivery | |
Secondary | Cesarean Delivery. | At Birth. | ||
Secondary | Vacuum Extraction Delivery. | At Birth. | ||
Secondary | Maternal Death. | During pregnancy or within 42 days after delivery | ||
Secondary | Postpartum Pulmonary Edema. | Within 42 days after delivery | ||
Secondary | Hematocrit =24% With Transfusion. | Within 42 days after delivery | ||
Secondary | Maternal Hospital Stay. | Duration of the time spend at the hospital after delivery (measured as days and weeks) | Within 42 days after delivery | |
Secondary | Gestational Age at Delivery. | At Delivery. | ||
Secondary | Perineal Lacerations. | Defined as first, second, third or fourth degree lacerations during birth. | At Birth. | |
Secondary | Number of Visits to Maternity Health Care During Pregnancy. | From gestation until delivery, on average during 9 months | ||
Secondary | Number of Visits at Tertiary Maternity Care Hospital. | From gestation until delivery, on average during 9 months | ||
Secondary | Fetal Death. | From 22nd gestational week until delivery | ||
Secondary | Neonatal Death. | Birth until 4 weeks' of age | ||
Secondary | Respiratory Distress Syndrome. | Birth until 4 weeks' of age | ||
Secondary | Intraventricular Hemorrhage, Grade III or IV. | Birth until 4 weeks' of age | ||
Secondary | Neonatal sepsis. | Birth until 4 weeks' of age | ||
Secondary | Necrotizing Enterocolitis. | Birth until 4 weeks' of age | ||
Secondary | Retinopathy of Prematurity. | Birth until 4 weeks' of age | ||
Secondary | Neonatal Hospital Stay. | Birth until 18 weeks' of age | ||
Secondary | Umbilical artery pulsatility index | Measured with Doppler ultrasound | At 30-32 gestational weeks | |
Secondary | Mean cerebral artery pulsatility index | Measured with Doppler ultrasound | At 30-32 gestational weeks | |
Secondary | Ductus venousus pulsatility index | Measured with Doppler ultrasound | At 30-32 gestational weeks | |
Secondary | Fetal weight estimation | Measured with ultrasound using fetal BPD, HC, AC and FL measurements (Hadlock) | At 30-32 gestational weeks | |
Secondary | Amniotic fluid measurement | Ultrasound measurements of maximum velocity pocket (cm) and amniotic fluid index (cm) | At 30-32 gestational weeks | |
Secondary | Estimation of fetal movement during ultrasound scan | Estimated as a whole with inspection of body movements, limb movements and breathing movement | At 30-32 gestational weeks | |
Secondary | Apgar Score =7 at 5 minutes. | At birth. | ||
Secondary | Blood transfusion. | Defined as red blood cell transfusion received by patient (mother or child). | From 22nd pregnancy week until four weeks after delivery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|